1. A wide scope of medications are included in the two classes of interest; while the anticholinergic list included an expected list with mild and more severe anticholinergic effects, the sedative group was more liberal, albeit clinically appropriate and novel for such studies. However, there is a range of adverse effects (be they anticholinergic or sedating) within each scope of exposure variables that has been left without evaluation. I suggest the authors consider a supplemental analysis using a more restricted list of each group to determine if the direction or strength of association differs. Additionally, other studies have questioned the contribution of 'mild' anticholinergics such as digoxin in contributing to cholinergic-related adverse events or geriatric syndromes. As such, restricting anticholinergics to those recognized in most scales as 'strong' (such as tricyclic antidepressants and first generation antihistamines) would be expected to strengthen relationships and would be an interesting supplemental analysis. Similarly, the sedative class includes a number of medications that may cause sedation as an intended or unintended effect, and much more liberal than other analyses that traditionally include benzodiazepines alone. Similar supplemental content with a restricted group of sedatives would be of interest.
2. The supplemental list of medications included in the two exposure groups should be moved to the main file (replacing table 2). Presenting the classes alone (such as opioids) leaves too many questions about which medications were included...and potentially incorrect extrapolation from readers.
3. The authors may consider another supplemental analysis excluding the residential care participants, or justify their inclusion, given that they represent a group inherently different than community-dwelling participants of a longitudinal aging study. In this cross-sectional study, limiting variability in population may allow better strength in the associations drawn by the analysis.
Minor editing suggestions: 1. In the abstract, results section: I suggest removing parentheses from the 2nd sentence (line 43) to indicate the gender-based evaluation.
2. additional limitations that should be noted: the CES-D question about appetite (to my knowledge) is not validated by itself; adherence to medications evaluated (along with dose and duration as noted by the authors) should be highlighted.
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GENERAL COMMENTS
Reviewer's report: An analysis of anticholinergic and sedative medicine effects on medicine induced deterioration and frailty: a cross sectional study This study aimed to examine any association between the use of medications with anticholinergic or sedative properties and medicine induced deterioration in physical or cognitive function or appetite and frailty using data from the Australian Longitudinal Study of Ageing. Abstract: The abstract is concisely written and is an accurate summation of the study and its findings. Specific comments are below Strengths and limitations -the authors mean sex and not gender, these are not interchangeable terms. This needs correction in a number of areas in the paper Introduction:
1. "Use of medicines with anticholinergic or sedative properties can directly lead to adverse events (5)" -this is true for any medication in the pharmacopaeia.
2.
Ideally, this section should end with the research question or hypothesis to be tested -the ultimate sentence could be moved to become the penultimate statement. Method: 1.
Why was duran's scale, rather than any other classification of anticholinergic drugs used? There are a number of such classifications, all of which differ. What proportion of medication were classified by expert opinion? 2.
Was grip strength performed with the dominant hand as a standard approach? Results: 1.
Well written and clear Discussion The use of the word "deterioration" suggests a temporal relationship which the authors cannot test -perhaps the use of the word "impairment" may be more suitable? Likewise, the authors use the term medicine-induced deterioration, again suggesting the causal association which they note they are unable to make. There appears to be a medication associated impairment in physical function and self reported lack of appetite would seem to be a balanced way of expressing the findings described herein.
The authors should also note the method of assessing appetite is subject to recall bias and is perhaps oversimplistic, there is no correction in the model for comorbidities other than the sum of conditions, many coexisting medical conditions require treatment with medications which have anticholinergic properties. These conditions, for example, urgency incontinence, may also form significant risk factors for reduced physical activity, falls and impaired ADL. The authors make no distinction between potent anticholinergic agents and those with "probable" anticholinergic properties, nor yet do they differentiate between peripherally acting and centrally acting agents. Given that these data were collected in 1992 -do the authors consider their findings relevant given the potential changes in management and / or prescribing practices in the intervening 27 years? The authors correctly point out that they are unable to ascribe a direction to the association they have found -older people with frailty and multimorbidity may indeed require these medications as part of their management and may indeed, derive benefit therefrom.
VERSION 1 -AUTHOR RESPONSE

REVIEWER 1
Reviewer Name: Noll Campbell Institution and Country: Purdue University, USA Please state any competing interests or state 'None declared': None declared Please leave your comments for the authors below Comment 1.
The authors are credited for their analysis highlighting the association of anticholinergic and sedative medications with physical dysfunction, frailty, and cognitive impairment. The measures are well described and the manuscript is generally well written as a whole. While the study design is a recognized limitation, the outcomes assessed are of interest. The following comments are offered to improve the quality and readability of the manuscript.
A wide scope of medications are included in the two classes of interest; while the anticholinergic list included an expected list with mild and more severe anticholinergic effects, the sedative group was more liberal, albeit clinically appropriate and novel for such studies. However, there is a range of adverse effects (be they anticholinergic or sedating) within each scope of exposure variables that has been left without evaluation. I suggest the authors consider a supplemental analysis using a more restricted list of each group to determine if the direction or strength of association differs. Additionally, other studies have questioned the contribution of 'mild' anticholinergics such as digoxin in contributing to cholinergic-related adverse events or geriatric syndromes. As such, restricting anticholinergics to those recognized in most scales as 'strong' (such as tricyclic antidepressants and first generation antihistamines) would be expected to strengthen relationships and would be an interesting supplemental analysis. Similarly, the sedative class includes a number of medications that may cause sedation as an intended or unintended effect, and much more liberal than other analyses that traditionally include benzodiazepines alone. Similar supplemental content with a restricted group of sedatives would be of interest.
Response
The focus of our present study was to study the association across a range of medicines that has potential anticholinergic/sedative properties without applying any restrictions. We did not limit the analysis to specific groups of sedatives and anticholinergics, including the ones suggested by the reviewer, due to the limitations in the existing anticholinergic scales and list of medicines with sedative properties. While many scales have been developed to measure the anticholinergic or sedative activity of medicines, none have been developed specifically for use in the Australian setting meaning that many relevant medicines are missing. Further, prior research has highlighted that there are a number of discrepancies between the scoring of the anticholinergic activity of medicines between the existing scales.
We located no comprehensive lists of medicines with anticholinergic or sedative effects, developed specifically for the Australian setting. For this reason, our team is currently developing this list; we presented our preliminary results at the Australian & New Zealand Society for Geriatric Medicine (ANZSGM) Annual Scientific Meeting, 13-15 May 2019 in Adelaide. We will first need to validate the list to determine whether older people using these medicines are at increased risk of harms. The next step would then be to use the list to perform the additional analysis including those suggested by the reviewer.
Comment 2. The supplemental list of medications included in the two exposure groups should be moved to the main file (replacing table 2). Presenting the classes alone (such as opioids) leaves too many questions about which medications were included...and potentially incorrect extrapolation from readers.
We appreciate the reviewer's suggestion. We have replaced the existing Table 2 with the supplemental list of medications in Additional File 1.
Comment 3. The authors may consider another supplemental analysis excluding the residential care participants, or justify their inclusion, given that they represent a group inherently different than community-dwelling participants of a longitudinal aging study. In this cross-sectional study, limiting variability in population may allow better strength in the associations drawn by the analysis.
When we excluded residential care participants in our analysis, there was no difference in the strength of association for any of the outcome measures. This is likely because the majority of the ALSA participants live in the community; only 6% of participants lived in residential care.1 We have revised the methods section to include more details on the participants: "At baseline, 93 percent of participants lived in the community and 6 percent lived in residential aged care." We agree with the reviewer participants in residential care are inherently different than communitydwelling participants; however, we decided it would be more useful to include all participants in the ALSA study (n=2087) for ease of comparison with other studies using the same population. Please state any competing interests or state 'None declared': none Please leave your comments for the authors below Reviewer's report: An analysis of anticholinergic and sedative medicine effects on medicine induced deterioration and frailty: a cross sectional study This study aimed to examine any association between the use of medications with anticholinergic or sedative properties and medicine induced deterioration in physical or cognitive function or appetite and frailty using data from the Australian Longitudinal Study of Ageing.
Comment 1
Abstract: The abstract is concisely written and is an accurate summation of the study and its findings. Specific comments are below Strengths and limitations -the authors mean sex and not gender, these are not interchangeable terms. This needs correction in a number of areas in the paper Response Thank you for pointing out our mistake. We have replaced the word "gender" with "sex" throughout the manuscript.
Comment 2
Introduction: 1. "Use of medicines with anticholinergic or sedative properties can directly lead to adverse events (5)" -this is true for any medication in the pharmacopaeia.
Response
We agree and have revised the sentence to "Use of medicines can directly lead to adverse events." Comment 3 Introduction: 2. Ideally, this section should end with the research question or hypothesis to be testedthe ultimate sentence could be moved to become the penultimate statement.
Response Thank you for the suggestion. We have revised the introduction, final paragraph by moving the final sentence to become the penultimate statement.
Comment 4
Method: 1. Why was duran's scale, rather than any other classification of anticholinergic drugs used? There are a number of such classifications, all of which differ. What proportion of medication were classified by expert opinion?
Response We used the Duran's scale because the authors collated a list of 100 medicines with clinically relevant anticholinergic properties based on seven previously published list of anticholinergic risk scales.1 For medicines commonly used in Australia that were not listed on Duran's scale, we referred to the lists used in an Australian study2 and the Veterans' MATES anticholinergic module. 3 We do not know the exact proportion of medications that were classified by expert opinion; the medicines were identified using various resources such as Australian Medicines Handbook, and the final list of medicines were reviewed by an expert panel in order to gain consensus for the information identified. To avoid any confusion, we have revised the sentence to "We identified medicines with anticholinergic properties using Duran's scale with the addition of other anticholinergic medicines used in previous Australian studies." Response We appreciate this positive comment.
Comment 7
Discussion: The use of the word "deterioration" suggests a temporal relationship which the authors cannot test -perhaps the use of the word "impairment" may be more suitable? Likewise, the authors use the term medicine-induced deterioration, again suggesting the causal association which they note they are unable to make. There appears to be a medication associated impairment in physical function and self reported lack of appetite would seem to be a balanced way of expressing the findings described herein.
Response Changes in patient conditions (e.g. physical function) are usually progressive and so we believe the word deterioration is more suitable to describe the process of a condition becoming progressively worse. We agree with the reviewer that the term "medicine-induced deterioration" imply that our results suggest there is a causal association. Therefore, throughout the manuscript we have either i) removed this term, or ii) revised the term to "deterioration associated with medicine use". For example: -We have removed the word "medicine-induced deterioration" in the manuscript title and changed the title to "An analysis of anticholinergic and sedative medicine effects on physical function, cognitive function, appetite and frailty: a cross-sectional study in Australia". -We have changed the hypothesis in the introduction section to "We hypothesized that use of medicines with anticholinergic or sedative properties is associated with decline in physical function and decline in cognitive function for anticholinergics or sedatives, poorer appetite for anticholinergics, and increased frailty." Comment 8 Discussion: The authors should also note the method of assessing appetite is subject to recall bias and is perhaps oversimplistic, there is no correction in the model for comorbidities other than the sum of conditions, many coexisting medical conditions require treatment with medications which have anticholinergic properties. These conditions, for example, urgency incontinence, may also form significant risk factors for reduced physical activity, falls and impaired ADL. The authors make no distinction between potent anticholinergic agents and those with "probable" anticholinergic properties, nor yet do they differentiate between peripherally acting and centrally acting agents. Response Thank you for the suggestions. We have added these as our study limitations: "Although the CES-D has been validated, the question on appetite has not been validated by itself. The method of assessing appetite may be subject to recall bias." "Although we adjusted our analysis for various potential confounding factors, there is a possibility of residual confounding or confounding by indication." "We did not differentiate between potent and probable anticholinergic medicines, or between peripherally and centrally acting medicines."
Comment 9
Given that these data were collected in 1992 -do the authors consider their findings relevant given the potential changes in management and / or prescribing practices in the intervening 27 years?
